Skip to search boxSkip to navigationSkip to main content

Virulence factors and mechanisms of antimicrobial resistance in Shigella strains from periurban areas of Lima (Peru)

  • Angela Lluque
    ,
  • Susan Mosquito
    ,
  • Cláudia Gomes
    ,
  • Maribel Riveros
    ,
  • David Durand
    ,
  • Drake H. Tilley
*Corresponding author for this work
  • Universidad Peruana Cayetano Heredia, Instituto de Medicina Tropical Alexander von Humboldt
    ,
  • Hospital Clínic – Universitat de Barcelona
    ,
  • U.S. Naval Medical Research Unit No. 6
    ,
  • School of Public Health, University of Texas
    ,
Research Output:
Contribution to journal
Article
Peer-review

Open access

Publication Information

Output type

Research Output:
Contribution to journal
Article
Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 480-490 (11 pages)

Journal (Volume, Issue Number)

International Journal of Medical Microbiology (Volume 305, Issue 4-5)

Publication milestones

  • Published - 01/06/2015

Publication status

Published - 01/06/2015

ISSN

1438-4221

Publication IDs

  • Scopus: 84983094642
  • PubMed: 25998616

Abstract

The study was aimed to describe the serotype, mechanisms of antimicrobial resistance, and virulence determinants in Shigella spp. isolated from Peruvian children. Eighty three Shigella spp. were serogrouped and serotyped being established the antibiotic susceptibility. The presence of 12 virulence factors (VF) and integrase 1 and 2, along with commonly found antibiotic resistance genes was established by PCR. S. flexneri was the most relevant serogroup (55 isolates, 66%), with serotype 2a most frequently detected (27 of 55, 49%), followed by S. boydii and S. sonnei at 12 isolates each (14%) and S. dysenteriae (four isolates, 5%). Fifty isolates (60%) were multi-drug resistant (MDR) including 100% of S. sonnei and 64% of S. flexneri. Resistance levels were high to trimethoprim-sulfamethoxazole (86%), tetracycline (74%), ampicillin (67%), and chloramphenicol (65%). Six isolates showed decreased azithromycin susceptibility. No isolate was resistant to nalidixic acid, ciprofloxacin, nitrofurantoin, or ceftriaxone. The most frequent resistance genes were sul2 (95%), tet(B) (92%), cat (80%), dfrA1 (47%), blaOXA-1 like (40%), with intl1 and intl2 detected in 51 and 52% of the isolates, respectively. Thirty-one different VF profiles were observed, being the ipaH (100%), sen (77%), virA and icsA (75%) genes the most frequently found. Differences in the prevalence of VF were observed between species with S. flexneri isolates, particularly serotype 2a, possessing high numbers of VF. In conclusion, this study highlights the high heterogeneity of Shigella VF and resistance genes, and prevalence of MDR organisms within this geographic region.

Funding Details

This work was supported by Agencia Española de Cooperación Internacional para el Desarrollo (AECID), Spain, Programa de Cooperación Interuniversitaria e Investigación Científica con Iberoamérica (D/019499/08, D/024648/09, D/030509/10, and A1/035720/11) (J.R and T.J.O) by the Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015) and Generalitat de Catalunya , Departament d’Universitats, Recerca i Societat de la Informació (2014 SGR 26) (JR) and by the National Institute of Child Health and Human Development , USA (Public Health Service award R01-HD051716) (TJO). JR has a fellowship from the program I3SNS, of the ISCIII (grant number: CES11/012), and CG has a predoctoral grant from the ISCIII (FI12/00561).
FundersFunding numbers
Generalitat de Catalunya , Departament d’Universitats, Recerca i Societat de la Informació
2014 SGR 26
Programa de Cooperación Interuniversitaria e Investigación Científica con Iberoamérica
A1/035720/11, D/030509/10, D/019499/08, D/024648/09
Spanish Network for the Research in Infectious Diseases
REIPI RD12/0015
NICHD
R01HD051716
NICHD
-
ISCIII
CES11/012, FI12/00561
AECID
-

Publication metrics

Metrics

Scopus
Citations

PlumX, opens in new tab

Captures
104
Social media
35
Citations
48

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well